Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Dr_Dan  – 2020-02-11 16:20 (391 d 01:09 ago) – Posting: # 21159
Views: 1,200

Dear qualityassurance
In case of a bioequivalence study, it also depends on whether the concomitant medication was
given obligatory to all subjects or was taken accidentally by one or maybe more subjects. In the first case, the effect for the test and the reference formulation would be the same and you do not need to argue. Otherwise, a detailed risk analysis should be carried out, which describes the estimated PK effects of the concomitant medication on the bioequivalence decision. If only a view subjects are affected a sensitivity analysis could be carried out.
I hope this helps.

Kind regards and have a nice day
Dr_Dan

Complete thread:

Activity
 Admin contact
21,371 posts in 4,463 threads, 1,495 registered users;
online 10 (0 registered, 10 guests [including 2 identified bots]).
Forum time: Monday 17:30 CET (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5